ERBB2 and breast carcinoma: Due to intermediate response to trastuzumab, MDA-MB-361 (IHC HER2 2 + /FISH HER2 + ) and MDA-MB-453 (IHC HER2 2 + /FISH HER2-) breast cancer cell lines were chosen for our subsequent studies.